2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1117

Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience
Abstract Number: 872

Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry
Abstract Number: 1668

Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Abstract Number: 33

GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes
Abstract Number: 2569

Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Abstract Number: 1494

Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Abstract Number: L13

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 807

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Abstract Number: 2317

Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis
Abstract Number: 693

Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study
Abstract Number: 232

Hand Digital Thermography Findings in Patients with Primary Fibromyalgia
Abstract Number: 1712

Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Abstract Number: 1125

Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Abstract Number: 247

Health Literacy, Adherence, and Quality of Life of Uveitis Patients
Abstract Number: 263

Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].